TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study Of 140 patients enrolled, 48.6% had stage IVM1b/c/d disease, ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to BioNTech, ...
The original PlayStation was one of the first consoles to have a modchip available for it. This was primarily due to the rise of cheap CD burners and blank discs that allowed game backups to be easily ...
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. Now, the rising class of bispecifics opened up an opportunity for the Swiss pharma to reenter the space from a ...
Mouse PD-1 is significantly weaker than human PD-1, which could have implications for using mice as models in PD-1 studies. Programmed cell death protein 1 (PD-1) has been a key target for cancer ...
The move will leave the stock trading at a tenth of its current price. These market giants have launched splits in order to make their shares more accessible to a broader range of investors.
The days of broad approvals for PD-1 inhibitors in stomach and esophageal cancers appear to be numbered. A group of external advisers to the FDA voted 10-2 that the use of PD-1 inhibitors in ...
Andrew Kessel was a breaking news writer for Investopedia until October 2025. He previously covered markets for Proactive Investors, with a focus on small-cap stocks in fintech, healthcare, mining, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback